Key result
Targeting microRNAs shows potential as a novel therapeutic strategy for pathological hypertrophy and cardiac failure.
This review highlights the potential of targeting microRNAs as a novel therapeutic approach for pathological cardiac hypertrophy and heart failure.
Requires rigorous trials before considering microRNA therapies in hypertrophy or HF; leaves open clinical translation.
MicroRNAs (miRNAs) are a novel class of endogenous, short, non-coding, posttranscriptional RNAs, which play important roles in regulating lots of important biological functions. Evidences show that altered expression of miRNAs are involved in pathological hypertrophy and cardiac failure, making it possible to target miRNAs as a novel therapy. In this review, we focus on very recent progresses in the regulation of miRNAs in pathological hypertrophy and cardiac failure. In addition, we also discuss the potential of using miRNAs as a new therapy for pathological hypertrophy and cardiac failure.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2015) conducted a review in Pathological hypertrophy and cardiac failure. Targeting microRNAs was evaluated. Targeting microRNAs shows potential as a novel therapeutic strategy for pathological hypertrophy and cardiac failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: